Known targets — ChEMBL curated mechanism
ACEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ATP4AATP4BAXLBTKCACNA1CCACNA1DCACNA1FCACNA1SCCR5CHRM2CHRM3CPT1BCPT2DPP4DRD1DRD2EGFRERBB2ERBB4FLT3HRH1HRH3HTR1AHTR2AHTR2BHTR2CHTR4JAK1JAK2JAK3KCNH2KMT2AMAP2K1MAP2K2MEN1MLNRMPLMTORPPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PLK4PPARGRENS1PR1SLC6A2SLC6A3SLC6A4SMOTYK2atpAatpBatpCatpDatpEatpFatpFHatpGpol
The experimentally established mechanism targets of Fumaric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.46 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.46 |
| ▸ | DRD1 known ✓ | P21728 | 1/20 | 0.46 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.46 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.46 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.46 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.46 |
| ▸ | HTR2C known ✓ | P28335 | 1/20 | 0.43 |
| ▸ | CCR3 | P51677 | 13/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.49 |
| ▸ | DRD4 | P21917 | 3/20 | 0.47 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.47 |
| ▸ | MTTP | P55157 | 2/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.46 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.46 |
| ▸ | DRD3 | P35462 | 1/20 | 0.46 |
| ▸ | MTR | Q99707 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6718424 | 0.95 | CCR3 (0.62) | CCR3CYP2D6DRD4MCHR1MTTP | |
| Hydrochloric Acid SCHEMBL6711564 | 0.95 | CCR3 (0.61) | CCR3CYP2D6DRD4MCHR1MTTP | |
| SCHEMBL6713973 | 0.89 | CCR3 (0.74) | CCR3CYP2D6MCHR1 | |
| SCHEMBL6714466 | 0.86 | DRD4 (0.58) | CCR3DRD4MCHR1MTTPCHRM2 | |
| Hydrochloric Acid SCHEMBL6711550 | 0.86 | DRD4 (0.57) | CCR3DRD4MCHR1MTTPCHRM2 | |
| SCHEMBL6711315 | 0.85 | CCR3 (0.62) | CCR3CYP2D6MCHR1CHRM2CHRM1 | |
| SCHEMBL6714695 | 0.85 | MCHR1 (0.57) | CCR3DRD4MCHR1MTTPCHRM2 | |
| SCHEMBL13419447 | 0.81 | CCR3 (0.46) | CCR3CYP2D6DRD4MCHR1MTTP | |
| SCHEMBL6711393 | 0.79 | CCR3 (0.61) | CCR3DRD4MCHR1 | |
| SCHEMBL6714383 | 0.78 | DRD4 (0.58) | CCR3DRD4MTTPCHRM2ADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040034028-A1 | 4-(biphenylcarbonylamino)piperidine derivatives as mtp inhibitors | MERCK PATENT GMBH (DE) | 2004-02-19 | — | — | US | claimed |
| US-20040034028-A1 | 4-(biphenylcarbonylamino)piperidine derivatives as mtp inhibitors | MERCK PATENT GMBH (DE) | 2004-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040034028-A1 | 4-(biphenylcarbonylamino)piperidine derivatives as mtp inhibitors | LIPC, CETP, MTTP | CHRM2 2977/4885ADRA2A 1881/4885DRD1 3376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.